The drug is a daily oral treatment for children 6 and up with chronic immune thrombocytopenia (ITP).
The Food and Drug Administration has approved a drug for a condition that can complicate treatment for hepatitis C.
Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.
The Food and Drug Administration has approved a GlaxoSmithKline drug for a rare blood disorder, GSK said Friday.
A drug made by Amgen maintained blood platelet counts in patients with an autoimmune bleeding disorder, according to results of a five-year study released Sunday.